## **NEUROLOGY INFUSION** Referral Form

**PHONE** 515.225.2930 | **FAX** 515.559.2495



Remove above por	tion before faxii	ng. Please comple	te the prescriptio	n form	in its e	entirety	and	fax with secur	e cover she	eet to the	number abo	ve.		
Patient Information								I						
Last Name	First Name DOB				Gender □ M □ F		□F	Last 4 SSN		Primary L		anguage		
Address				City	City Stat					ZIP				
Email		W	ork Pho	ne			Cell Pho	ne						
Primary Contact Method (check one)						☐ Text ☐ Email ☐ Primary Caregiver ☐ DO NOT CONTACT								
Primary Caregiver/Alt Contact	Name (If applicab	le)	Alt Contac	t Emai	I					Alt Conta	ct Phone			
Prescriber Information														
Name of Contact Sending Refe	erral		Title			Р	refer	red Contact Met	hod (check	one) 🗆 Eı	mail 🗆 Phon	e 🗆 Fax		
Referral Contact Email					Office	Phone			Offic	e Fax				
Practice/Facility Name						Prescriber Name/Specialty								
Address						City State ZIP								
7.00.000		* Dlamas in also	d			-16:				State		•		
		* Please Includ	de a copy of the	ront d	ina bo	ICK Of In	surc	ince cara. *						
Clinical Information - P									rapy Start Da					
Patient New to Therapy ☐ Naïve/New Start ☐ Therapy Restart ☐ Existing Treatment														
Sample/Starter Provided? ☐ No ☐ Yes, Provide Qty: Date Provided:						Patient Height (cm/in): Weight (kg/lbs): Date Obtained:								
Therapies Tried and Failed (ple	ase list medicatio	ns)												
Other/Concomitant Medication	ns (please list)													
Allergies □ NKDA □ Drug A	llergies (please lis	t)												
Ship to Address ☐ Home ☐	Prescriber's Offic	e 🗆 Other (please	list)											
□ G35 Multipl □ G60.3 Idiop □ G61.0 Gullai □ G61.81 Chro □ G62.89 Multiple  Prescription Informatio	athic Progressive n-Barre Syndromo nic Inflammatory tifocal Motor Neur	Demyelinating Polyropathy	oy state law.			L10.0 Per M33.20 F M33.90 C Other	mphi Polym Derm	enia Gravis with gus Vulgaris nyositis organ in atopolymyositis	volvement u	unspecified vement un				
In order for a brand name p or your state-specific requir	roduct to be dis ed language to	pensed, the presci prohibit substitution	riber must handv	ot a vo	alid pre	escriptic								
		DOSE/STRENGTH		DIRE	CTION	S					QTY	REFILLS		
☐ Immune Globulin ☐	IV	grams grams			□ 1 mg/kg/hr for first 30 minutes, then increase every 30 minutes to a max rate of 6m/kg/hr not to exceed 300 ml/hr							□1 year □		
□ Lemtrada □	IV	□12 mg/day			☐ Initial Dose – 12 mg/day over 4 hours for 5 consecutive days ☐ Maintenance Dose – 12 mg/day IV over 4 hours for 3 consecutive dates 12 months after initial dose							□1 year		
□ Ocrevus □	IV	□ 300 mg/10 mL vial			☐ Starter Dose – Infuse 300 mg IV over no less than 2.5 hours on day 1 and day 15 ☐ Maintenance Dose – Infuse 600 mg IV over no less than 3.5 hours every 6 months							□1 year		
☐ Vascular Access Method	☐ Peripheral	☐ Central ☐	Other:											
□ Normal Saline □ D5W	IV	□3 mL □5 mL			☐ Before and after infusion						□1 month □3 months	□1 year		
☐ Heparin 10 units/mL ☐ Heparin 100 units/mL	IV	□ 3 mL □ 5 mL			☐ After infusion ☐					□1 month □3 months	□1 year			
☐ Diphenhydramine ☐	IV	□ 25 mg □ 50 mg			☐ After infusion ☐ PRN Allergic Reaction:					_	□ With each infusion	□ 1 year		
□ Acetaminophen □	PO	□ 325 mg □ 500 mg □ 1 gm			□ Pre-Med:						☐ With each infusion	□1 year		
		□ Adult 1:1000, 0.3 m □ Peds 1:2000, 0.3 m				phylaxis g Dose: _				_	□ Once	□1 year		
□ Other:														
Prescriber Signature		 Date		pervisi	ng Phy	sician Sig	gnatu	ıre (where requi	 red by state	law) Ni	PI#	Date		

Note: The information contained in this document will become a legal prescription. Prescriber is to comply with his/her state specific pharmacy and medical board guidelines such as e-prescribing, state specific prescription form, fax language, number of prescriptions allowed on a single prescription form, etc. If more than one page is required, make additional copies. Non-compliance with state specific requirements could result in outreach to the prescriber. Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information, which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material.